Identified adult patients receiving prescriptions in England’s CNS-stimulant and ADHD-drug category increased 40% in 2025/26. For a professional paying for an assessment, the next question matters just as much as the diagnosis: who will manage treatment, review its benefits, and coordinate care when another clinician takes over?
Key findings
426,504: identified patients in the CNS-stimulant and ADHD-drug category in 2025/26.
4,243,160: prescription items in the same category and year.
31%: the rounded annual increase in identified patients overall.
40% versus 17%: the reported increases among adults and children, respectively.
Source: NHSBSA’s July 2026 release. These figures cover NHS prescribing in England subsequently dispensed in the community. They are not counts of new ADHD diagnoses, and the category includes medications with other uses. [1]
Adult and child prescribing grew at different rates
The adult increase was larger, but neither percentage measures ADHD prevalence. Private prescriptions are outside this NHS series. [1]
What the data show
The latest year extends a longer increase in recorded prescribing activity. NHSBSA counted 162,838 identified patients in 2020/21, rising to 426,504 in 2025/26. Prescription items increased from 1,832,286 to 4,243,160 over those selected years. An item is not a dose or a unique person. [1]
| Fiscal year | Identified patients | Prescription items |
|---|---|---|
| 2020/21 | 162,838 | 1,832,286 |
| 2021/22 | 192,105 | 2,132,077 |
| 2022/23 | 233,474 | 2,544,087 |
| 2023/24 | 277,640 | 2,914,733 |
| 2024/25 | 326,450 | 3,381,200 |
| 2025/26 | 426,504 | 4,243,160 |
Source: NHSBSA, Tables 1 and 2. Patient-identification completeness changes over time. These counts are not population-adjusted rates or a record restricted to confirmed ADHD. [1]
A rapid increase is a finding, not an explanation. Recognition, access routes, prescribing practice, and movement between services are possible subjects for investigation. The aggregate figures do not tell us how much each contributed.
An assessment can also happen long after difficulties began. The prescription record lacks the developmental history and clinical information needed to distinguish newly recognized difficulties from new onset. A headline about prescribing should not become a claim that ADHD suddenly became more common by the same percentage.
The private pathway is only partly visible
The NHS series does not provide a complete record of private assessments, prescriptions, or follow-up. That matters for families able to pay for faster access. Their care may appear in one part of the public record but not another.
A person could receive an assessment privately and later obtain NHS prescriptions. Another could remain entirely within private care. A prescription transaction cannot reconstruct either pathway. Comparing public and private treatment requires a service history rather than an assumption about where the first appointment occurred.
The Independent ADHD Taskforce identified concerns about access and continuity in England. Its reports provide context for the prescribing trend, not proof that one particular service problem explains every increase. [2]
An assessment is not a complete treatment plan
For a founder or executive, a scheduled assessment can feel like a defined purchase: an appointment, a fee, and a report. But the assessment may identify ADHD, suggest another explanation, or require more information. Payment should not predetermine its conclusion.
NICE places diagnosis within a specialist clinical assessment, including impairment and the wider history. It also calls for medication review covering benefits, adverse effects, clinical need, and effects on education or employment. Renewing a prescription is not the whole review. [3]
Before choosing a service, ask what the fee includes and who explains the assessment. Clarify who manages treatment, how progress is reviewed, and what happens if another clinician needs additional information before accepting a handover. These are practical questions about accountability, not demands for a guaranteed diagnosis or outcome.
The age comparison should prompt attention to adult services without creating stereotypes. The figures do not identify executives, founders, income, or wealth. Occupational success is neither evidence of ADHD nor a reason to dismiss a person’s difficulties. Assessment needs to remain open to the individual’s history and several possible explanations.
The recent patient-count trajectory
Source: NHSBSA. The chart shows recorded patient counts, with exact figures in the table. It does not isolate the causes of growth. [1]
For international families, the handover matters
Consider a professional assessed in London who later spends several months in Dubai or Zurich. This is an illustrative situation, not a measured pattern in the dataset. Before traveling, the person needs clarity about access to records, follow-up, and responsibility for decisions.
The assessment history, medication history, response, and unresolved questions should travel with the care plan. A new clinician should not have to reconstruct the entire pathway from a prescription list. Family support can help with logistics while respecting the patient’s consent and clinical decision-making.
The UK, United States, Germany, Switzerland, Netherlands, and GCC countries are not one prescribing environment. A service cannot assume that a clinician elsewhere will accept a particular arrangement. Local requirements should be checked with the professionals and authorities involved.
What better outcome reporting would measure
A useful study would follow the difficulties that prompted treatment, appropriate symptom measures, adverse effects, daily functioning, and continuity of care. It would report how long participants were followed and how many could be reached. Treatment changes and early departures should remain visible.
For an executive, improved functioning should not simply mean working longer. More sustainable organization, fewer avoidable difficulties, and a manageable balance of responsibilities may be more meaningful goals. Those goals need to be agreed with the person, not inferred from a job title.
Providers should also distinguish patient satisfaction from clinical improvement. Feeling heard is valuable, but it does not establish whether symptoms improved or benefits lasted. A brief positive survey cannot substitute for a defined follow-up process with an explicit denominator.
What to clarify before paying for a pathway
A useful written proposal should distinguish assessment from any subsequent treatment. It should explain what information the assessment requires, who discusses the findings, and how uncertainty is handled. An appointment is not made more rigorous merely by being longer or more expensive. The relevant question is whether the clinical process addresses the person’s history and current difficulties.
Handover arrangements should be explicit rather than assumed. A receiving clinician may need to examine records, ask further questions, or make a different clinical judgment. Before relying on an arrangement, the patient should know who remains responsible if the transfer does not proceed. This is particularly important when an initial service sells assessment separately from ongoing care.
Progress also needs a starting point. Recording the problems that motivated the appointment makes later review more informative than asking whether treatment felt helpful. For example, a patient may want to manage tasks more consistently or experience fewer difficulties at home. These are illustrative goals, not promised effects of a particular medication or a substitute for appropriate clinical measures.
The same approach protects against an overly narrow definition of success. A person may report better concentration but troublesome adverse effects, or improved work organization without improvement in another important area. A clinical review needs to consider the overall balance rather than elevate the most favorable change into a complete recovery claim. NICE’s medication-review recommendations provide the relevant clinical context. [3]
For families, involvement should support the process without determining its conclusion. A relative may help assemble developmental history or describe practical concerns. The clinician still needs the patient’s account and an assessment that is open to alternative explanations. A successful career should not settle the question in either direction, and a strong wish for an explanation should not become a predetermined diagnosis.
For media coverage, these questions offer a more concrete investigation than another headline about rising demand. A report could compare what services disclose about assessment scope, follow-up, and transfer responsibilities. That would require a documented provider sample and an opportunity to correct factual errors. This article identifies the questions but does not present an audit of private clinics.
What the numbers cannot tell us
The source does not estimate the private ADHD market, executive prevalence, overdiagnosis, or treatment success. It records a drug category rather than a verified diagnostic cohort. The adult and child changes are rounded source figures, and long-term comparisons need the source’s patient-identification notes.
No provider audit or public-private outcome comparison was conducted. The article’s care questions are an interpretation of what patients need to clarify, not findings that any named service has failed to provide those arrangements.
The bottom line
Prescribing activity is expanding. A fast assessment may be useful, but it does not measure the quality of everything that follows. For families with choice, the stronger comparison is between complete, accountable care pathways rather than the speed of the first appointment.
For journalists
Key comparison: identified adult patient counts increased 40%, compared with 17% among children, in England’s 2025/26 CNS-stimulant and ADHD-drug series.
Important caveat: these are prescribing counts, not new diagnoses or an executive-specific survey.
Suggested attribution: THE BALANCE analysis of NHSBSA prescribing data and published ADHD care guidance.
Methodology and sources
This analysis retains the July 23, 2026 NHSBSA release and its fiscal years. Tables preserve exact counts; chart labels are rounded. It uses aggregate records, taskforce reports, and clinical guidance, not private patient records. No causal effect of wealth or type of provider is estimated.
